Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
AVXL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Anavex Life Sciences Corp.NASDAQ: AVXL
Research & Development · Q1 FY2026 · quarter ended Dec 2025
Research & development declines year over year
Q1 FY2026 research & development of $4.66M fell 55.4% year over year, behind the -27.0% change in trailing-twelve-month research & development. Sequentially, it fell 36.2% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -55.4% toward the trailing-twelve-month pace of -27.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 37.59M USD
- Year-over-year change
- -10.1%
- 4-year CAGR
- +3.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 37.59M | -10.1% |
| FY2024 | 2024-09-30 | 41.84M | -4.3% |
| FY2023 | 2023-09-30 | 43.72M | +15.3% |
| FY2022 | 2022-09-30 | 37.92M | +15.0% |
| FY2021 | 2021-09-30 | 32.98M | — |
Research & Development vs competitors
How AVXL compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -27.0% is the 9th highest of 10, against a peer median of +12.8%.
- Over three fiscal years its annual growth of -0.3% compares with a peer median of -2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $254.4M USD | -28.3% | -3.5% | 284.6% | |
| LTM Mar 2026 | $228.65M USD | +12.8% | -2.0% | 260.4% | |
| LTM Mar 2026 | $220.82M USD | +62.1% | +69.0% | — | |
| LTM Sep 2026 | $133.6M USD | +39.6% | -6.2% | — | |
| LTM Mar 2026 | $128.82M USD | +9.2% | +14.8% | 161.5% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $101.27M USD | +35.7% | +54.7% | — |
| LTM Mar 2026 | €85.57M EUR | +12.6% | -6.7% | 54.7% | |
| LTM Mar 2026 | $84.33M USD | +24.0% | +11.4% | 4593.1% | |
| LTM Mar 2026 | $69.1M USD | -13.8% | -14.9% | 194.4% | |
| LTM Dec 2025 | $31.8M USD | -27.0% | -0.3% | — | |
| Peer median (excluding AVXL) | — | +12.8% | -2.0% | 227.4% | |
Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.98M | 37.92M | 43.72M | 41.84M | 37.59M |
| Selling, General & Admin | 9.02M | 13.07M | 12.05M | 11.04M | 13.82M |
| Operating Expenses | 42M | 50.99M | 55.76M | 52.88M | 51.41M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (37.64M) | (47.62M) | (46.54M) | (43M) | (46.38M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (42M) | (50.99M) | (55.76M) | (52.88M) | (51.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 26K | 947K | 6.52M | 7.32M | 4.68M |
| Interest Expense | 0 | 0 | 964K | 0 | 0 |
| Other Income / Expenses | 4.36M | 3.37M | 8.26M | 9.88M | 5.03M |
| Income Before Tax | (37.64M) | (47.62M) | (47.51M) | (43M) | (46.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 268K | 358K | 0 | 0 | 0 |
| Net Income | (37.91M) | (47.98M) | (47.51M) | (43M) | (46.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) |
| EPS (Diluted) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) |
| Weighted Avg Shares | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M |
| Weighted Avg Shares (Diluted) | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M |
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.